Chinese biopharmaceutical firm Gensciences has raked in a total of over 800 million yuan ($123.6 million) through its Series A and Series B rounds of financing as the life science sector is gaining more traction during the global health crisis.
Investors in the Series A round include investment companies IDG Capital, New Alliance Capital, and Huaige Capital. The Series A backers made follow-on investments in the subsequent Series B round as well.
